These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 12431966)

  • 1. Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: evidence for activity in non-small-cell lung cancer.
    Herbst RS; Madden TL; Tran HT; Blumenschein GR; Meyers CA; Seabrooke LF; Khuri FR; Puduvalli VK; Allgood V; Fritsche HA; Hinton L; Newman RA; Crane EA; Fossella FV; Dordal M; Goodin T; Hong WK
    J Clin Oncol; 2002 Nov; 20(22):4440-7. PubMed ID: 12431966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and pharmacokinetic study of TNP-470, an angiogenesis inhibitor, in combination with paclitaxel and carboplatin in patients with solid tumors.
    Tran HT; Blumenschein GR; Lu C; Meyers CA; Papadimitrakopoulou V; Fossella FV; Zinner R; Madden T; Smythe LG; Puduvalli VK; Munden R; Truong M; Herbst RS
    Cancer Chemother Pharmacol; 2004 Oct; 54(4):308-14. PubMed ID: 15184994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multi-center study of two dose levels of paclitaxel with carboplatin in locally advanced and metastatic non-small cell lung cancer (NSCLC).
    Glorieux P; Ortmanns P; Marien S; Degives R; Degraeve D; Potvin M; Grauwels D; Schallier D
    Anticancer Res; 2001; 21(2B):1487-94. PubMed ID: 11396237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I/IIA trial of continuous five-day infusion of squalamine lactate (MSI-1256F) plus carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.
    Herbst RS; Hammond LA; Carbone DP; Tran HT; Holroyd KJ; Desai A; Williams JI; Bekele BN; Hait H; Allgood V; Solomon S; Schiller JH
    Clin Cancer Res; 2003 Sep; 9(11):4108-15. PubMed ID: 14519633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase I and pharmacokinetic study of TNP-470 administered weekly to patients with advanced cancer.
    Bhargava P; Marshall JL; Rizvi N; Dahut W; Yoe J; Figuera M; Phipps K; Ong VS; Kato A; Hawkins MJ
    Clin Cancer Res; 1999 Aug; 5(8):1989-95. PubMed ID: 10473076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I trial of the matrix metalloproteinase inhibitor marimastat combined with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.
    Goffin JR; Anderson IC; Supko JG; Eder JP; Shapiro GI; Lynch TJ; Shipp M; Johnson BE; Skarin AT
    Clin Cancer Res; 2005 May; 11(9):3417-24. PubMed ID: 15867243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B.
    Akerley W; Herndon JE; Egorin MJ; Lyss AP; Kindler HL; Savarese DM; Sherman CA; Rosen DM; Hollis D; Ratain MJ; Green MR
    Cancer; 2003 May; 97(10):2480-6. PubMed ID: 12733147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I pharmacokinetic study of bexarotene with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (NSCLC).
    Rodon J; Jacobs CD; Chu Q; Rowinsky EK; Lopez-Anaya A; Takimoto CH; Wakelee HA
    Cancer Chemother Pharmacol; 2012 Mar; 69(3):825-34. PubMed ID: 22057853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paclitaxel (1-hour) and carboplatin (area under the concentration-time curve 7.5) in advanced non-small cell lung cancer: a phase II study of the Fox Chase Cancer Center and its network.
    Langer CJ; Millenson M; Rosvold E; Litwin S; McAleer CA; Bonjo CA; Ozols R
    Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-81-S12-88. PubMed ID: 9331128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer.
    Thienelt CD; Bunn PA; Hanna N; Rosenberg A; Needle MN; Long ME; Gustafson DL; Kelly K
    J Clin Oncol; 2005 Dec; 23(34):8786-93. PubMed ID: 16246975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paclitaxel in lung cancer: 1-hour infusions given alone or in combination chemotherapy.
    Hainsworth JD; Greco FA
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):45-9. PubMed ID: 8643970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Weekly paclitaxel and nedaplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer: a phase I/II study.
    Hasegawa Y; Takanashi S; Okudera K; Aoki M; Basaki K; Kondo H; Takahata T; Yasui-Furukori N; Tateishi T; Abe Y; Okumura K
    Jpn J Clin Oncol; 2004 Nov; 34(11):647-53. PubMed ID: 15613553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC).
    Cohen RB; Langer CJ; Simon GR; Eisenberg PD; Hainsworth JD; Madajewicz S; Cosgriff TM; Pierce K; Xu H; Liau K; Healey D
    Cancer Chemother Pharmacol; 2007 Jun; 60(1):81-9. PubMed ID: 17031646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination paclitaxel (1-hour) and carboplatin (AUC 7.5) in advanced non-small cell lung cancer: a phase II study by the Fox Chase Cancer Center Network.
    Langer CJ; Millenson M; O'Dwyer P; Kosierowski R; Alexander R; Litwin S; McAleer CA; Bonjo CA; Ozols R
    Semin Oncol; 1996 Dec; 23(6 Suppl 16):35-41. PubMed ID: 9007119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined effects of TNP-470 and taxol in human non-small cell lung cancer cell lines.
    Satoh H; Ishikawa H; Fujimoto M; Fujiwara M; Yamashita YT; Yazawa T; Ohtsuka M; Hasegawa S; Kamma H
    Anticancer Res; 1998; 18(2A):1027-30. PubMed ID: 9615759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of paclitaxel and bevacizumab in heavily pre-treated non-small-cell lung cancer (NSCLC) patients: a case series study on 15 patients.
    Le Moulec S; Hadoux J; Gontier E; Chargari C; Helissey C; Lamand V; Tanz R; Farace F; Vedrine L; Bonardel G; Soria JC; Besse B
    Bull Cancer; 2013 Dec; 100(12):30-7. PubMed ID: 24316967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose escalation study of paclitaxel in combination with fixed-dose irinotecan in patients with advanced non-small cell lung cancer (JCOG 9807).
    Yamada K; Ikehara M; Tanaka G; Nomura I; Oshita F; Noda K
    Oncology; 2004; 66(2):94-100. PubMed ID: 15138360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose-escalating and pharmacokinetic study of a weekly combination of paclitaxel and carboplatin for inoperable non-small cell lung cancer: JCOG 9910-DI.
    Naoki K; Kunikane H; Fujii T; Tsujimura S; Hida N; Okamoto H; Watanabe K
    Jpn J Clin Oncol; 2009 Sep; 39(9):569-75. PubMed ID: 19520687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose-finding and sequencing study of paclitaxel and carboplatin in non-small cell lung cancer.
    Giaccone G; Huizing M; Postmus PE; ten Bokkel Huinink WW; Koolen M; van Zandwijk N; Vermorken JB; Beijnen JH; Dalesio O; Pinedo HM
    Semin Oncol; 1995 Aug; 22(4 Suppl 9):78-82. PubMed ID: 7544030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paclitaxel and carboplatin: a phase I study in advanced non-small cell lung cancer.
    Paccagnella A; Favaretto A; Oniga F; Ossana L
    Semin Oncol; 1996 Dec; 23(6 Suppl 16):76-9. PubMed ID: 9007128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.